ATC Group: R03DC Leukotriene receptor antagonists

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R03DC in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R03 Drugs for obstructive airway diseases
3 R03D Other systemic drugs for obstructive airway diseases
4 R03DC Leukotriene receptor antagonists

Group R03DC contents

Code Title
R03DC01 Zafirlukast
R03DC02 Pranlukast
R03DC03 Montelukast
R03DC04 Ibudilast
R03DC53

Active ingredients in R03DC

Active Ingredient

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Τhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.

Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slowreacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.

Related product monographs

Document Type Information Source  
 ACCOLATE Coated tablet MPI, US: SPL/Old FDA, National Drug Code (US)
 MONKASTA Film-coated tablet MPI, EU: SmPC Medicines Authority (MT)
 SINGULAIR Tablet / Chewable Tablet / Granule MPI, US: SPL/PLR FDA, National Drug Code (US)
Go to ATC index
⇈